Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Immix Biopharma (IMMX) had its price target raised by Mizuho from $14.00 to $15.00. They now have an "outperform" rating on the stock.
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma (IMMX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $23.00 price target on the stock.
Immix Biopharma (IMMX) had its price target raised by HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.